Scientists identify innate lymphoid cells (ILCs) as possible targets for immunotherapies as their activation makes murine pancreatic tumours sensitive to PD-1 checkpoint inhibitors.
List view / Grid view
Filter the results
A team of scientists in the United States has successfully used a drug, which blocks AHR receptors, to prevent and treat obesity in mice. Their findings have spurred further research into the receptors’ association with diet and the gut microbiome.
Research indicates that activation of the RICTOR/mTORC2 pathway advances cancer metastasis and suggests that inhibiting this signalling may make chemotherapy more effective against colon cancer.
Researchers have discovered that pancreatic cancer cells secrete IL-1β to suppress the immune system and suggest antibody treatments as a therapy for pancreatic ductal adenocarcinoma.
Drug Target Review lists its 10 most popular news stories from 2019, summarising the drug targets that you wanted to read about.
A mechanism has been revealed that could be used to deny RAS mutant tumour cells (which is known to encourage the growth seen in pancreatic cancer patients) of a key survival mechanism.
This article highlights some of the most recent drug target discoveries that could be used to develop and design a treatment for pancreatic cancer.
A study conducted on human pancreatic tumours transplanted in mice reveals promise for an effective therapy in the future, say researchers.
A study has demonstrated that a novel vaccine design for pancreatic cancer has been successful in mice, doubling survival time.
Peptide-based nanoparticles have been designed which can suppress pancreatic cancer growth without the toxic side effects.
Cells containing Meflin play a role in restraining the progression of pancreatic cancer and could lead to new therapies against the disease.
Researchers have shown that blocking a particular enzyme causes chemotherapy to become more effective against pancreatic cancers in pre-clinical studies.
Researchers have developed a new cocktail of drugs that shrink pancreatic tumours in mice by blocking pathways that cancer cells use.
New findings show that the environment for pancreatic cancers plays a role in its metastasis, revealing a new potential drug target.